Crit Care Med:IV氨基酸补充对ICU患者死亡率的影响可能依赖于…

2018-08-09 吴星 环球医学

2018年8月,澳大利亚和丹麦学者在《Crit Care Med》发表的一项多中心随机试验的事后亚组分析表明,IV氨基酸补充对ICU患者死亡率的影响可能依赖于肾功能。

2018年8月,澳大利亚和丹麦学者在《Crit Care Med》发表的一项多中心随机试验的事后亚组分析表明,IV氨基酸补充对ICU患者死亡率的影响可能依赖于肾功能。

目的:旨在调查基线的肾功能是否可以确定ICU患者能从蛋白摄入的增加(2.0g/kg/d)中获益。

设计:一项多中心、2期、随机临床试验的事后假设生成亚组分析。所有分析都根据意向治疗进行,并维持分组情况。90天死亡率为首要结局。

地点:澳大利亚和新西兰16家医院的ICUs。

患者:预期在研究ICU停留超过2天的成年重症患者。

干预:随机分配到接受每天补充IV氨基酸100g,以实现总体蛋白摄入为2.0g/kg/d的组中或标准营养护理组。

测量指标和主要结果:总共474名患者被随机分组:标准护理组235人,IV氨基酸补充组239人。基线肾功能和研究中的氨基酸补充具有统计学显着的交互作用(p交互作用=0.026)。随机分组时肾功能正常的患者亚组中,接受氨基酸补充的患者研究90天前死亡的可能性较低(协变量调整风险差,-7.9%;95% CI,-15.1~-0.7;p=0.034)。此外,氨基酸补充可显着增加这些患者的估计肾小球滤过率(重复测量治疗×时间交互作用p=0.009)。基线肾功能不全和/或处于急性肾损伤进展风险的患者亚组中,研究干预对死亡率无显着影响(协变量调整风险差,-0.6%;95% CI,-16.2~15.2;p=0.95)。

结论:在这项事后假设生成的亚组分析中,研究者观察到,随机分配到蛋白摄入增加组(2.0g/kg/d)的肾功能正常的ICU患者的死亡率降低,且估计肾小球滤过率改善。研究者强烈建议,在该治疗推荐用于常规医疗前,在具有较低偏倚风险的试验中对这些结果予以验证。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1983595, encodeId=3fd1198359513, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jan 24 06:53:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860855, encodeId=1637186085559, content=<a href='/topic/show?id=5e746403ed5' target=_blank style='color:#2F92EE;'>#氨基酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64037, encryptionId=5e746403ed5, topicName=氨基酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Oct 01 06:53:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339896, encodeId=0ff7339896df, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 21 10:29:46 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595369, encodeId=a10315953695d, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Sat Aug 11 13:53:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609044, encodeId=b24216090440e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Aug 11 13:53:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337594, encodeId=e26833e59464, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Aug 09 23:34:22 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337583, encodeId=542e33e58343, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Aug 09 23:05:53 CST 2018, time=2018-08-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1983595, encodeId=3fd1198359513, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jan 24 06:53:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860855, encodeId=1637186085559, content=<a href='/topic/show?id=5e746403ed5' target=_blank style='color:#2F92EE;'>#氨基酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64037, encryptionId=5e746403ed5, topicName=氨基酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Oct 01 06:53:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339896, encodeId=0ff7339896df, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 21 10:29:46 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595369, encodeId=a10315953695d, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Sat Aug 11 13:53:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609044, encodeId=b24216090440e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Aug 11 13:53:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337594, encodeId=e26833e59464, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Aug 09 23:34:22 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337583, encodeId=542e33e58343, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Aug 09 23:05:53 CST 2018, time=2018-08-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1983595, encodeId=3fd1198359513, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jan 24 06:53:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860855, encodeId=1637186085559, content=<a href='/topic/show?id=5e746403ed5' target=_blank style='color:#2F92EE;'>#氨基酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64037, encryptionId=5e746403ed5, topicName=氨基酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Oct 01 06:53:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339896, encodeId=0ff7339896df, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 21 10:29:46 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595369, encodeId=a10315953695d, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Sat Aug 11 13:53:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609044, encodeId=b24216090440e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Aug 11 13:53:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337594, encodeId=e26833e59464, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Aug 09 23:34:22 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337583, encodeId=542e33e58343, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Aug 09 23:05:53 CST 2018, time=2018-08-09, status=1, ipAttribution=)]
    2018-08-21 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1983595, encodeId=3fd1198359513, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jan 24 06:53:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860855, encodeId=1637186085559, content=<a href='/topic/show?id=5e746403ed5' target=_blank style='color:#2F92EE;'>#氨基酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64037, encryptionId=5e746403ed5, topicName=氨基酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Oct 01 06:53:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339896, encodeId=0ff7339896df, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 21 10:29:46 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595369, encodeId=a10315953695d, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Sat Aug 11 13:53:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609044, encodeId=b24216090440e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Aug 11 13:53:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337594, encodeId=e26833e59464, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Aug 09 23:34:22 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337583, encodeId=542e33e58343, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Aug 09 23:05:53 CST 2018, time=2018-08-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1983595, encodeId=3fd1198359513, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jan 24 06:53:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860855, encodeId=1637186085559, content=<a href='/topic/show?id=5e746403ed5' target=_blank style='color:#2F92EE;'>#氨基酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64037, encryptionId=5e746403ed5, topicName=氨基酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Oct 01 06:53:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339896, encodeId=0ff7339896df, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 21 10:29:46 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595369, encodeId=a10315953695d, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Sat Aug 11 13:53:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609044, encodeId=b24216090440e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Aug 11 13:53:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337594, encodeId=e26833e59464, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Aug 09 23:34:22 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337583, encodeId=542e33e58343, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Aug 09 23:05:53 CST 2018, time=2018-08-09, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1983595, encodeId=3fd1198359513, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jan 24 06:53:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860855, encodeId=1637186085559, content=<a href='/topic/show?id=5e746403ed5' target=_blank style='color:#2F92EE;'>#氨基酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64037, encryptionId=5e746403ed5, topicName=氨基酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Oct 01 06:53:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339896, encodeId=0ff7339896df, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 21 10:29:46 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595369, encodeId=a10315953695d, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Sat Aug 11 13:53:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609044, encodeId=b24216090440e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Aug 11 13:53:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337594, encodeId=e26833e59464, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Aug 09 23:34:22 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337583, encodeId=542e33e58343, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Aug 09 23:05:53 CST 2018, time=2018-08-09, status=1, ipAttribution=)]
    2018-08-09 惠映实验室

    学习了,谢谢分享。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1983595, encodeId=3fd1198359513, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jan 24 06:53:00 CST 2019, time=2019-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1860855, encodeId=1637186085559, content=<a href='/topic/show?id=5e746403ed5' target=_blank style='color:#2F92EE;'>#氨基酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64037, encryptionId=5e746403ed5, topicName=氨基酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Oct 01 06:53:00 CST 2018, time=2018-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339896, encodeId=0ff7339896df, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 21 10:29:46 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595369, encodeId=a10315953695d, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Sat Aug 11 13:53:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609044, encodeId=b24216090440e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Aug 11 13:53:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337594, encodeId=e26833e59464, content=学习了,谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Aug 09 23:34:22 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337583, encodeId=542e33e58343, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Aug 09 23:05:53 CST 2018, time=2018-08-09, status=1, ipAttribution=)]
    2018-08-09 清风拂面

    谢谢分享学习

    0

相关资讯

Cell Metab:科学家揭示低蛋白饮食抗癌机制,激活免疫反应是关键

在最近的《细胞代谢》杂志中,来自法国的Jean-Ehrland Ricci博士带领团队给出了答案,可行!而且他们还发现了这其中的分子机制。低蛋白饮食可以激活一条关键的IRE1α/RIG1信号通路,诱导内质网中的未折叠蛋白反应,杀死癌细胞。

输了瓶氨基酸,这个村卫生站赔偿26万

案例回放患者女,49岁,因“腰痛1天”于2016年5月10日16:00左右来该卫生站就诊。既往有高血压病史。医生考虑为“体虚,腰痛查因”(医生提交的资料中未见体格检查记录),治疗上予以“复方氨基酸注射液18AA 500ml(厂家:江苏亚邦生缘药业有限公司,批号:国药准字H19993413)静脉滴注”。输液过程中患者未见其它不适。约20:20 输液完毕,患者家属接其回家,约过10分钟左右,家属来电称

Gut:肠道微生物代谢产物、氨基酸代谢物与胰岛素敏感性和葡萄糖代谢!

由此可见,该研究的结果强调了TMAO、胆碱和左旋肉碱变化在肥胖患者减肥干预过程中改善胰岛素敏感性的重要性。膳食脂肪摄入可改变TMAO与胰岛素敏感性和糖代谢之间的关系。

Nat Med:癌细胞已哭晕!人类又整新招断其粮道!

早前,探索君曾报道过一种廉价感冒药被证实有望“饿死”癌细胞。现在,《Nature Medicine》期刊又提供了一种通过阻断营养而消灭癌细胞的“妙招”:科学家们首次发现一种新型的化合物,能够切断肿瘤氨基酸代谢通路,从而抑制肿瘤生长。

Nat Commun:一种氨基酸水平影响乳腺癌扩散

英国癌症研究会发布的一项新研究显示,天冬酰胺这种氨基酸在乳腺癌扩散过程中扮演重要角色。限制小鼠体内的天冬酰胺水平能降低癌细胞扩散几率,这一发现有助未来给病患提供更好的治疗方案。

病人输注氨基酸后死亡,家属一番话感慨万千!

“医闹”不是天外来客,更不是来自于我们未知的六道轮回,而是双方信任坍塌造成的。